drugset / Trial / NCT04752020

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

NCT04752020

Phase 0 Completed 25 enrolled Massachusetts Eye and Ear Infirmary
NaSingle-groupOpen-labelTreatment

Summary

This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts. The anticipated enrollment is 25 patients.

Timeline

Start
2021-03-28
Primary completion
2023-06-28
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule Topical